201 related articles for article (PubMed ID: 35700522)
1. Isolation of circulating exosomes and identification of exosomal PD-L1 for predicting immunotherapy response.
Zhang J; Zhu Y; Guan M; Liu Y; Lv M; Zhang C; Zhang H; Zhang Z
Nanoscale; 2022 Jun; 14(25):8995-9003. PubMed ID: 35700522
[TBL] [Abstract][Full Text] [Related]
2. Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction.
Huang M; Yang J; Wang T; Song J; Xia J; Wu L; Wang W; Wu Q; Zhu Z; Song Y; Yang C
Angew Chem Int Ed Engl; 2020 Mar; 59(12):4800-4805. PubMed ID: 31912940
[TBL] [Abstract][Full Text] [Related]
3. Nanoplasmonic Sandwich Immunoassay for Tumor-Derived Exosome Detection and Exosomal PD-L1 Profiling.
Wang C; Huang CH; Gao Z; Shen J; He J; MacLachlan A; Ma C; Chang Y; Yang W; Cai Y; Lou Y; Dai S; Chen W; Li F; Chen P
ACS Sens; 2021 Sep; 6(9):3308-3319. PubMed ID: 34494426
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer.
Park SJ; Park JY; Shin K; Hong TH; Lee M; Kim Y; Kim IH
BMC Cancer; 2023 May; 23(1):389. PubMed ID: 37127565
[TBL] [Abstract][Full Text] [Related]
5. Sensitive Detection of Exosomal Proteins via a Compact Surface Plasmon Resonance Biosensor for Cancer Diagnosis.
Liu C; Zeng X; An Z; Yang Y; Eisenbaum M; Gu X; Jornet JM; Dy GK; Reid ME; Gan Q; Wu Y
ACS Sens; 2018 Aug; 3(8):1471-1479. PubMed ID: 30019892
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
[TBL] [Abstract][Full Text] [Related]
7. Exosomal PD-L1 in cancer and other fields: recent advances and perspectives.
Lu MM; Yang Y
Front Immunol; 2024; 15():1395332. PubMed ID: 38726017
[TBL] [Abstract][Full Text] [Related]
8. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Ayala-Mar S; Donoso-Quezada J; González-Valdez J
J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
Yin Z; Yu M; Ma T; Zhang C; Huang S; Karimzadeh MR; Momtazi-Borojeni AA; Chen S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472857
[TBL] [Abstract][Full Text] [Related]
10. Quantification-Promoted Discovery of Glycosylated Exosomal PD-L1 as a Potential Tumor Biomarker.
Zhu L; Xu Y; Kang S; Lin B; Zhang C; You Z; Lin H; Yang C; Song Y
Small Methods; 2022 Sep; 6(9):e2200549. PubMed ID: 35810463
[TBL] [Abstract][Full Text] [Related]
11. The role of exosomal PD-L1 in tumor progression and immunotherapy.
Xie F; Xu M; Lu J; Mao L; Wang S
Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
[TBL] [Abstract][Full Text] [Related]
12. The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target.
Ye L; Zhu Z; Chen X; Zhang H; Huang J; Gu S; Zhao X
Cells; 2021 Nov; 10(11):. PubMed ID: 34831468
[TBL] [Abstract][Full Text] [Related]
13. Coaxial dual-path electrochemical biosensing and logic strategy-based detection of lung cancer-derived exosomal PD-L1.
Liu J; Liu Z; Zhao C; Jiao Y; Li B; Shi J; Chen Z; Zhang Z
Nanoscale; 2024 May; 16(18):8950-8959. PubMed ID: 38630023
[TBL] [Abstract][Full Text] [Related]
14. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents.
Turiello R; Capone M; Morretta E; Monti MC; Madonna G; Azzaro R; Del Gaudio P; Simeone E; Sorrentino A; Ascierto PA; Morello S
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35273100
[TBL] [Abstract][Full Text] [Related]
15. The Detection of Exosomal PD-L1 in Peripheral Blood.
Wang R; Yang Y; Huang J; Yao Y
Methods Mol Biol; 2023; 2695():195-212. PubMed ID: 37450120
[TBL] [Abstract][Full Text] [Related]
16. Multivalence-Actuated DNA Nanomachines Enable Bicolor Exosomal Phenotyping and PD-L1-Guided Therapy Monitoring.
Jin D; Peng XX; Qin Y; Wu P; Lu H; Wang L; Huang J; Li Y; Zhang Y; Zhang GJ; Yang F
Anal Chem; 2020 Jul; 92(14):9877-9886. PubMed ID: 32551501
[TBL] [Abstract][Full Text] [Related]
17. Tumor-derived exosomal PD-L1 in progression of cancer and immunotherapy.
Rasihashemi SZ; Rezazadeh Gavgani E; Majidazar R; Seraji P; Oladghaffari M; Kazemi T; Lotfinejad P
J Cell Physiol; 2022 Mar; 237(3):1648-1660. PubMed ID: 34825383
[TBL] [Abstract][Full Text] [Related]
18. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.
Wang J; Zhang H; Sun X; Wang X; Ren T; Huang Y; Zhang R; Zheng B; Guo W
J Nanobiotechnology; 2020 Oct; 18(1):151. PubMed ID: 33092576
[TBL] [Abstract][Full Text] [Related]
19. Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets.
Liang B; Hu X; Ding Y; Liu M
J Cell Physiol; 2021 Jun; 236(6):4138-4151. PubMed ID: 33275291
[TBL] [Abstract][Full Text] [Related]
20. High Throughput and Noninvasive Exosomal PD-L1 Detection for Accurate Immunotherapy Response Prediction via Tim4-Functionalized Magnetic Core-Shell Metal-Organic Frameworks.
Wang H; Liu Y; Zhang L; Li X; Zhao G; Song Z; Jia Y; Qiao X
Anal Chem; 2023 Dec; 95(49):18268-18277. PubMed ID: 38011622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
